Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 19/20 | 0.68 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.45 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.42 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5447468 | 0.88 | CXCR2 (0.52) | CXCR2PDK1PDK2PDK3PDK4 | |
| Trifluoroacetic Acid SCHEMBL4588697 | 0.83 | CXCR2 (0.87) | CXCR2CX3CR1 | |
| SCHEMBL6564144 | 0.81 | CXCR2 (1.00) | CXCR2CX3CR1 | |
| SCHEMBL27571726 | 0.76 | CXCR2 (0.47) | CXCR2CX3CR1 | |
| Elubrixin SCHEMBL30515706 | 0.75 | CXCR2 (1.00) | CXCR2 | |
| Elubrixin SCHEMBL1562280 | 0.75 | CXCR2 (1.00) | CXCR2 | |
| Elubrixin SCHEMBL1741720 | 0.74 | CXCR2 (0.98) | CXCR2 | |
| SCHEMBL1568743 | 0.74 | CXCR2 (0.67) | CXCR2 | |
| SCHEMBL4593429 | 0.73 | CXCR2 (0.84) | CXCR2CX3CR1 | |
| SCHEMBL4587568 | 0.72 | CXCR2 (0.82) | CXCR2CX3CR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249625-A1 | Il-8 Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION | 2007-10-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249625-A1 | Il-8 Receptor Antagonists | CXCL8, CCR8, IL1RN | CXCR2 9/4885CX3CR1 32/4885PDK1 3242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.